Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).
| Active ingredient / Technology | Brand name | Indication range* |
| Capsaicin | Qutenza® | EU indication: Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. US indication: Indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. |
| Fixed-dose combination of Esomeprazole and Naproxen | Vimovo® | In adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient. |
| Lidocaine | Versatis® | EU and Peru indication: Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults. Latin America indication: Treatment of localised neuropathic pain, including pain associated with a previous herpes zoster infection (postherpetic neuralgia). |
| Zolmitriptan | Zomig® AscoTop ® Nasal |
Oral formulations: In adults aged 18 years and older for acute treatment of migraine headache with or without aura. Nasal spray: In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura, and in adults for the treatment of cluster headache.** |
| Testosterone undecanoate |
Nebido® |
Treatment of male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. |
| Esomeprazole | Nexium® |
20 mg; 40 mg gastro-resistant tablets:
In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori |
| Rosuvastatin | Crestor® | Treatment of hypercholesterolaemia Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. Prevention of cardiovascular events Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors. |
| Naloxegol | Moventig® Movantik® |
MoventigTM Indication Europe: MoventigTM is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MovantikTM Indication US: MovantikTM is an opioid antagonist indicated for the treatment of OIC in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. |
| Glyceryl trinitrate rectal ointment | Rectogesic® 4mg/g | Relief of pain associated with chronic anal fissures. |
| Granisetron transdermal patch | Sancusco® | Prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult. |
*Status: February 2026. If not otherwise mentioned the EU SmPC approved at the time of review is used as a basis. Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC)
** Indication in UK: Zomig Nasal Spray is indicated for the acute treatment of migraine with or without aura.
# see SmPC for ‘Nexium™ 10 mg gastro-resistant granules for oral suspension, sachet’ and for ‘Nexium™ 40 mg Powder for solution for injection/infusion’
